Real-world dose adjustments occurred in patients with primary immunodeficiency who switched from intravenous immunoglobulin to subcutaneous immunoglobulin 20%, with resulting implications for payers, patients, and plasma collection and supply.
Xiaolan Ye, PhD
Advertisement
Articles by Xiaolan Ye, PhD
Advertisement
Latest Updated Articles
Real-World Immunoglobulin Dose Adjustments and Impact on Utilization and CostsPublished: April 18th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
CDC Layoffs Raise Questions About the Future of Public Health Surveillance
2
From $200,000 in Student Loan Debt to Becoming a 7-Figure Pharmacist
3
Inhaled Insulin Demonstrates Comparable Safety, Lung Function, and Efficacy to Injectable Insulin in Type 1 Diabetes
4
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
5
